Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
Authors
Keywords
-
Journal
LANCET
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-03
DOI
10.1016/s0140-6736(23)02230-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fluid retention and heart failure in the PRECISION trial
- (2023) Donald E Kohan et al. LANCET
- The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
- (2023) Vandana Veenit et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
- (2023) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
- (2022) Markus P Schlaich et al. LANCET
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
- (2022) Colin Baigent et al. LANCET
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
- (2021) Simke W. Waijer et al. Clinical Journal of the American Society of Nephrology
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Niels Jongs et al. Lancet Diabetes & Endocrinology
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Novel strategy to monitor fluid absorption and blood loss during urological endoscopic surgery
- (2020) Yunxin Zhang et al. Translational Andrology and Urology
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
- (2020) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
- (2019) Kitty J Jager et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Endothelin and endothelin antagonists in chronic kidney disease
- (2014) Donald E Kohan et al. KIDNEY INTERNATIONAL
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Endothelin antagonists for diabetic and non-diabetic chronic kidney disease
- (2012) Donald E. Kohan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
- (2011) D. E. Kohan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Zibotentan for the treatment of castrate-resistant prostate cancer
- (2010) Dale R Shepard et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now